One of the hottest startups in the AI-generated drug discovery landscape has corralled $400 million in a Series C that triples its paper value from its last round of financing.
Chai Discovery, one of the hottest startups in the AI-generated drug discovery landscape, has corralled $400 million in a Series C that triples its paper …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Chai Discovery raises $400M as AI drug discovery booms
Chai Discovery triples to $3.8B in 7 months as OpenAI-backed drug designer lands $400M after Novartis deal — TFN
Chai Discovery raises $400M for AI drug discovery as big pharma bets on machine learning over blockchain
Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma - SiliconANGLE
Chai Discovery Announces Collaboration with Novartis to Advance AI-Driven Antibody Discovery
China's DeepSeek considers new fundraising after first round - The Economic Times
China’s DeepSeek eyes US$70b valuation in new talks weeks after first round
DeepSeek plans new fundraising for investors who missed out: sources
Chai Discovery's $400M Series C triples its value to $3.8bn, a fresh sign that AI drug discovery has moved from promise to…
Chai Discovery raised $400 million at a $3.8 billion valuation, tripling its worth in seven months and pushing total funding…
Chai Discovery is raising $400M at a $3.4B valuation for AI drug discovery, backed by Pfizer, Eli Lilly, and OpenAI, raising…
Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma - SiliconANGLE
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to…
Start-up has attracted investment from Menlo Ventures and Yuri Milner’s DST Global Partners
